Panel Issued New CAR T-Cell Therapy Guidelines
Updated recommendations aim to improve safety for patients undergoing CAR T-cell therapy for autoimmune diseases.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you trust that new medical cell therapies are adequately tested before use in patients?
An international panel released new guidelines for the use of CAR T-cell therapy to treat autoimmune diseases. The framework addresses patient selection and toxicity management following safety concerns.
Why it matters
The guidance seeks to standardize clinical practices, as standard oncologic therapies may trigger new or unexpected side effects in patients with autoimmune conditions. Establishing consistent monitoring protocols is essential to patient safety during these complex treatments.
The guidelines reflect 10 years of experience with oncologic CAR T products. They follow the report of 3 patient fatalities that prompted companies to pause research trials.
The players
European Society for Blood and Marrow Transplantation
This organization is a non-profit entity dedicated to the advancement of research and education regarding blood and marrow transplantation.
International Society for Cell and Gene Therapy
This is a global professional society focused on the translation of cell-based therapies into safe and effective clinical applications.
Novartis
This is a multinational pharmaceutical corporation that develops and manufactures innovative medicines and cell therapies.
Bristol Myers Squibb
This is a global biopharmaceutical company known for its work in immunology, oncology, and cardiovascular disease treatments.
The details
The recommendations mandate that therapies occur within clinical trials or under the supervision of multidisciplinary teams comprising cell therapists and rheumatologists or neurologists. Practitioners are advised to report all treated patients to established registries like the EBMT Registry.
Timeline
August 2026: Novartis and Bristol Myers Squibb paused clinical trials.
October 5, 2026: Updated guidelines were published in The Lancet Rheumatology.
The Big Picture
The guidelines standardize the use of the EBMT Registry to track patient outcomes across international borders. This framework integrates autoimmune indications into the broader trajectory of cellular therapy monitoring established by oncologic programs.
Patients may see changes in how their treatment plans are managed, with a new emphasis on collaborative care between cell specialists and their primary rheumatologists. These measures aim to mitigate unexpected side effects and clarify the safety requirements for upcoming clinical trials.
The takeaway
Patients considering these therapies should ensure their medical team is following the latest multidisciplinary management protocols. Staying informed about current trial safety data is critical for those participating in emerging autoimmune research.
Further reading
For more information on the evolution of cellular medicines, visit the Biotech section.
Live Poll
Do you trust that new medical cell therapies are adequately tested before use in patients?
